Macarena Jimenez-Hernandez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Changes in Infarct Volume and Cerebral Edema After Mechanical Thrombectomy in Patients With Stroke Randomized to ApTOLL or Placebo: A Secondary Analysis of APRIL Trial.

Changes in Infarct Volume and Cerebral Edema After Mechanical Thrombectomy in Patients With Stroke Randomized to ApTOLL or Placebo: A Secondary Analysis of APRIL Trial.

Journal: Stroke

Published: July 18, 2025

Gut Microbiota, Bacterial Translocation, and Stroke: Current Knowledge and Future Directions.

Gut Microbiota, Bacterial Translocation, and Stroke: Current Knowledge and Future Directions.

Journal: Biomedicines

Published: October 25, 2024

Clinical trial to compare safety and tolerability between intravenous infusion and bolus intravenous injection of ApTOLL in healthy volunteers.

Clinical trial to compare safety and tolerability between intravenous infusion and bolus intravenous injection of ApTOLL in healthy volunteers.

Journal: Molecular therapy. Nucleic acids

Published: July 17, 2024

Aptamers as new promising entities for therapeutics: our experience from the neurological diseases.

Aptamers as new promising entities for therapeutics: our experience from the neurological diseases.

Journal: Neural regeneration research

Published: June 17, 2024

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization.

Cerebroprotective Effects of the TLR4-Binding DNA Aptamer ApTOLL in a Rat Model of Ischemic Stroke and Thrombectomy Recanalization.

Journal: Pharmaceutics

Published: April 24, 2024

Enhancing Enrollment in Acute Stroke Trials: Current State and Consensus Recommendations.

Enhancing Enrollment in Acute Stroke Trials: Current State and Consensus Recommendations.

Journal: Stroke

Published: September 11, 2023

ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis.

ApTOLL: A new therapeutic aptamer for cytoprotection and (re)myelination after multiple sclerosis.

Journal: British journal of pharmacology

Published: July 04, 2023

Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial.

Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial.

Journal: JAMA neurology

Published: June 20, 2023

Defective hippocampal neurogenesis underlies cognitive impairment by carotid stenosis-induced cerebral hypoperfusion in mice.

Defective hippocampal neurogenesis underlies cognitive impairment by carotid stenosis-induced cerebral hypoperfusion in mice.

Journal: Frontiers in cellular neuroscience

Published: May 09, 2023

APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke.

APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke.

Journal: Frontiers in neurology

Published: December 19, 2022

Beneficial effect of TLR4 blockade by a specific aptamer antagonist after acute myocardial infarction.

Beneficial effect of TLR4 blockade by a specific aptamer antagonist after acute myocardial infarction.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 19, 2022

First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers.

First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers.

Journal: Molecular therapy. Nucleic acids

Published: August 09, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026